INTRODUCTION
============

Processive transcription antitermination, a system best characterized in bacteriophage lambda (λ), involves hijacking and structural modification of host RNA polymerase (RNAP) by a complex of proteins and RNA, enabling the regulation of transcription through downstream termination sites. During lytic infection, phage λ utilizes this process to control the timing of transcription of particular genes essential for lytic growth as the virus switches from early, to delayed-early, to late gene expression ([@B1]). Many other viruses, including the HIV provirus, use analogous systems of transcription control through the use of RNA regulatory elements ([@B2]).

The λ antitermination complex consists of phage N protein, N-utilization (*nut*) RNA control sequences BoxA and BoxB, and host proteins referred to as N-utilization substances A, B, E and G (NusA, NusB, NusE and NusG). NusE is also known as ribosomal protein S10 of the 30 S ribosome subunit ([@B3]). As such, this protein exhibits moonlighting behavior by playing roles in distinct complexes involved in transcription or translation in a mutually exclusive manner ([@B4],[@B5]). BoxA and BoxB facilitate antitermination through several protein--RNA interactions. BoxA binds to the host NusB--NusE heterodimer ([@B6],[@B7]) and the BoxB stem loop binds to the N protein ([@B8; @B9; @B10; @B11]). A spacer region, to which NusA binds ([@B12]), separates these two RNA segments. Although less well understood, a similar mechanism is employed by the bacterial host in the transcription control of ribosomal RNA operons (*rrn*) using the same Nus factors, other ribosomal proteins, a host-encoded BoxA RNA and a BoxB-like RNA (reviewed in [@B13]).

The λ antitermination complex assembly likely begins with the association of NusB with BoxA as its sequence is transcribed. This is in concert with the formation of the NusB--NusE heterodimer, which facilitates and strengthens the binding to other transcription elongation components including N protein, BoxB, NusA, NusG and RNAP ([@B14]). Association of NusB, NusE and BoxA is therefore a regulatory event during the initial assembly of the complete antitermination complex ([@B4],[@B15]), and has been chosen as a key element for our structural investigation. Moreover, the NusB--NusE heterodimer has been shown to bind BoxA with greater affinity than either protein alone ([@B7],[@B16],[@B17]). The ribosome binding loop of *Escherichia coli* (*Ec*) NusE/S10 was shown to be dispensable for λ transcription antitermination by genetic replacement of the loop with a serine ([@B4]). The crystal structure of the *Ec*NusB--NusE complex was thus solved and UV cross-linking studies were used in an attempt to identify the amino acids responsible for binding of BoxA RNAs encoded in the *Ec rrn* operons (*Ec*BoxA) ([@B4]). Those experiments provided a general indication of the BoxA binding region, but atomic details necessary to understand the protein--RNA interactions are still lacking, and have proven to be a major experimental hurdle. As an alternative approach, we used orthologous proteins from *Aquifex aeolicus* (*Aa*). Although phylogenetically divergent, the NusB and NusE proteins from these two bacteria are similar, sharing amino acid sequence identities of 28 and 53%, respectively ([Figure 1](#F1){ref-type="fig"}A and B). Furthermore, we previously reported the solution structure of *Aa*NusB and demonstrated similar protein--protein interactions at the NusB--NusE interface for the two bacterial systems ([@B18]). In this study, we have also replaced the ribosome binding loop of *Aa*NusE with a single serine ([Figure 1](#F1){ref-type="fig"}B) to improve solubility and provide a more globular structure conducive for crystallization. Figure 1.Sequence and structure of NusB, NusE and *rrn* BoxA. (**A** and **B**) Structure-based sequence alignments of NusB and NusE from *A. aeolicus* (Swiss-Prot codes: O66530, O66430) and *E. coli* (Swiss-Prot codes: P0A780, P0A7R5). Residues shaded in gray were removed by genetic manipulation and replaced by a serine to form modified versions of *Ec*NusE ([@B4]) and *Aa*NusE (this work). (**C**) Sequence alignment of the *rrn* BoxA regions. Nucleotides in red denote positions that are different in the *E. coli* sequence relative to that of *A. aeolicus.* (**D**) Stereo representation of *Aa*BoxA (chain R) as it exists in the crystal structure of *Aa*NusB--NusE--BoxA, including electron density from a 2*F*~o~−*F*~c~ omit map contoured at 1σ.

An *Aa rrn* BoxA (*Aa*BoxA) was identified by sequence comparison with *Ec rrn* operons, and a synthetic 12-mer BoxA RNA (5′-GGC UCC UUG GCA-3′) was used in crystallization experiments ([Figure 1](#F1){ref-type="fig"}C). This particular 12-mer RNA exists as a stable duplex at room temperature, with a melting temperature of ∼32°C (see [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)), and was therefore utilized as both single-stranded BoxA and generic double-stranded (ds) RNA by varying experimental temperatures. In this work, we outline the detailed RNA interactions of *Aa*NusB--NusE with both BoxA and dsRNA, as well as the structure--functional significance of each. We also demonstrate by NMR and biophysical measurements that the *Aa*NusB--BoxA interactions are equivalent in *E. coli*. Lastly, our genetic complementation assays for *Aa*NusB in *E. coli* support the functional interpretation of the new crystal structures and demonstrate cross-species NusB--NusE--RNA interaction.

MATERIALS AND METHODS
=====================

Cloning, coexpression and purification of *Aa*NusB-NusE
-------------------------------------------------------

*Aa*NusB was prepared as described ([@B18]). To coexpress the *Aa*NusB--NusE complex, genes encoding *Aa*NusE (residues 47--68 replaced with a single Ser) and *Aa*NusB were cloned into suitable donor vectors, followed by multi-site recombination into a tagless destination vector (pDEST42) using Gateway® cloning technology (Invitrogen, Carlsbad, CA, USA). The proteins were coexpressed in *E. coli* and soluble lysate was incubated for 30 min at 90°C and clarified by centrifugation. The sample was purified by ion-exchange chromatography. Further details are provided in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1).

Crystallization and structure determination
-------------------------------------------

Crystals of *Aa*NusB--NusE--BoxA were grown at 37°C. Crystals of *Aa*NusB--NusE--dsRNA were grown at room temperature. All data were collected at the Advanced Photon Source and processed with HKL 3000 ([@B19]). Molecular replacements were performed using Phaser ([@B20]). Model building and refinement were carried out using the programs COOT ([@B21]) and PHENIX ([@B22]), respectively. All figures were generated using PyMol ([@B23]). Data, refinement statistics and other structural information are summarized in [Table 1](#T1){ref-type="table"}. Further details are provided in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1). Table 1.X-ray diffraction data and refinement statistics*Aa*NusB-- NusE--BoxA*Aa*NusB-- NusE--dsRNACrystal    Space group*P*2~1~*P*2~1~2~1~2~1~    Unit cell parameters     *a* (Å)40.576.8     *b* (Å)113.079.9     *c* (Å)65.8106.6     *β* (°)102.990Matthews coefficient (Å^3^/Da)2.42.6DataOverall (last shell)Overall/(last shell)    Resolution (Å)40.00--1.90 (1.97--1.90)50.00--2.20 (2.28--2.20)    Unique reflections42 602 (3354)32 257 (3160)    Redundancy5.0 (2.8)5.7 (5.5)    Completeness (%)94.2 (74.5)94.7 (94.5)    *R*~merge~[^a^](#TF1){ref-type="table-fn"}0.102 (0.520)0.057 (0.542)    *I*/σ~(~*~I~*~)~19.3 (1.7)26.7 (3.1)Refinement[^b^](#TF2){ref-type="table-fn"}Overall/(last shell)Overall/(last shell)    Resolution (Å)35.67--1.90 (1.95--1.90)33.64--2.20 (2.26--2.20)    Unique reflections42 498 (2150)32 201 (2634)    Completeness (%)93.9 (71)94.6 (94)    Data in the test set2160 (98)1659 (135)    *R*~work~0.169 (0.258)0.201 (0.273)    *R*~free~0.202 (0.292)0.239 (0.357)Structure    Observed Electron Density     *Aa*NusB (A)1--1380--69, 73--134[^c^](#TF3){ref-type="table-fn"}     *Aa*NusB (B)1--1370--137[^c^](#TF3){ref-type="table-fn"}     *Aa*NusE (J)[^d^](#TF4){ref-type="table-fn"}3--47, 69--1024--47, 69--103     *Aa*NusE (K)[^d^](#TF4){ref-type="table-fn"}3--47, 69--1034--47, 69--103     *Aa*BoxA (R)1--9[^e^](#TF5){ref-type="table-fn"}1--12[^f^](#TF6){ref-type="table-fn"}     *Aa*BoxA (S)1--105--12    Protein non-H atoms/B (Å^2^)4066/32.93524/64.7    RNA non-H atoms/B (Å^2^)432/37.7375/88.4    Water oxygen atoms/B (Å^2^)240/40.398/56.9    Other solvent atoms/B (Å^2^)78/56.435/91.5    R.m.s.d.     Bond lengths (Å)0.0070.004     Bond angles (°)1.0280.723    Coordinate error (Å)0.230.33    Ramachandran plot     Favored regions (%)99.399.0     Disallowed regions (%)0.00.0[^2][^3][^4][^5][^6][^7]

*Ec*NusB and *Ec*BoxA preparations and biophysical measurements
---------------------------------------------------------------

*Ec*NusB proteins were cloned, expressed and purified using the methods previously described ([@B18],[@B24]). NMR spectra were collected on Varian Inova spectrometers at either 600 or 800 MHz equipped with ChiliProbes. Sequential backbone assignments were made using standard triple resonance pulse sequences ([@B25]). Data were processed and analyzed using NMRPipe ([@B26]) and CCPNMR ([@B27]) and scripts therein. Sequential backbone and side-chain assignments of the *Ec*NusB*-*BoxA complex were complete for ∼95% of the protein. Analytical ultracentrifugation was performed at 25 000 rpm, 20°C, using a Beckman XL-1 Optima analytical ultracentrifuge (Beckman Coulter, Inc., Brea, CA, USA). The protein--RNA interaction studies were performed using a VP-ITC Microcalorimeter (MicroCal LLC, Northampton, MA, USA) at 25 or 35°C. The integrated heat-of-interaction values were fit using the Origin 7.0-based ITC data analysis software (MicroCal). Further details are provided in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1).

Functional assay for *Aa*NusB complementation in *E. coli*
----------------------------------------------------------

The entire *nusB* ORF (open reading frame) was deleted from the *E. coli* chromosome by recombineering as described ([@B28]). The *Ec* W3110 *ΔnusB* cells were transformed with plasmids expressing *Aa* or *Ec*NusB proteins or with naked pET vector as a control. The transformed cells were then analyzed for cell growth at different temperatures. To assay for the NusB requirement in the growth of phage λ, the *ΔnusB* cells containing the *Aa*NusB, *Ec*NusB or control plasmids, were plated, spotted with serial phage dilutions and incubated at 42°C to observe the formation of λ plaques. Further details are provided in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1).

RESULTS
=======

The NusB--NusE heterodimer recognizes 8 nt of BoxA
--------------------------------------------------

Crystal data, refinement and structural details are provided in [Table 1](#T1){ref-type="table"}. Representative electron density is shown in [Figure 1](#F1){ref-type="fig"}D. The crystal structure of *Aa*NusB--NusE--BoxA contains two independent copies each of *Aa*NusB, *Aa*NusE and *Aa*BoxA in the form of a dimer of ternary complexes ([Supplementary Figure S1A](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)), which can be superimposed with a root-mean-square deviation (r.m.s.d.) of 0.3 Å ([Supplementary Figure S1B](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Dynamic light-scattering experiments demonstrate that the interaction between the two complexes is both concentration and temperature dependent and that *Aa*NusB--NusE is monomeric under native conditions. The four protein molecules are interconnected through two distinct NusB--NusE interfaces: one biologically relevant and previously observed in solution ([@B18]) and the other induced by dimerization. The data revealed electron density for eight and 10 out of the 12 nt for BoxA molecules R and S, respectively, but the 10th nucleobase of chain S is buried between symmetry-related *Aa*NusB molecules in the crystal lattice and its position is thus considered an artifact of crystallization ([Supplementary Figure S1C](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)).

The *Aa*BoxA RNA demonstrates extensive base-specific interactions with protein, beginning at the N-terminal amino group of *Aa*NusB and ending at the *Aa*NusB--NusE interface ([Figure 2](#F2){ref-type="fig"} and [Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). These contacts include both hydrogen bonds and hydrophobic interactions with bases of *Aa*BoxA nucleotides 1--8. The *Aa*BoxA--protein interface comprises at least 30 interactions with an average of 3--4 interactions per nucleotide, but all protein--RNA interactions except those involving *Aa*BoxA-U8 are specific to *Aa*NusB alone ([Figure 2](#F2){ref-type="fig"}B and C). The direct contribution to *Aa*BoxA binding by *Aa*NusE is observed in the *Aa*BoxA-U8 nucleotide binding site formed by the *Aa*NusB--NusE protein--protein interface ([Figure 2](#F2){ref-type="fig"}A and C). Within this binding pocket, *Aa*BoxA*-*U8 is held tightly in place through hydrophobic stacking interactions with both faces of the uracil ring, provided by *Aa*NusB-F122 and *Aa*NusE-R16. The guanidinium group of R16 also donates a hydrogen bond directly to the 2′-O of the *Aa*BoxA-U8 ribose. Aside from spatial constraints, base-specificity of *Aa*BoxA-U8 is achieved through two hydrogen bonds: one, which exists between the backbone NH of *Aa*NusB-G78 and O4 of the uracil base and the other between endocyclic N3 and *Aa*NusB-E81. *Aa*NusE-H15 donates a hydrogen bond that is bifurcated by the carboxylate oxygen atoms of *Aa*NusB-E81, thereby stabilizing the E81 side chain in a conformation favorable for *Aa*BoxA-U8 recognition. Together, these contributions by *Aa*NusE enhance *Aa*BoxA affinity and specificity. *Aa*NusB-K118 also binds to this region of *Aa*BoxA through ionic interaction with the phosphate group of *Aa*BoxA-G9 ([Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). However, information pertaining to the ribose and nucleobase moieties of *Aa*BoxA*-*G9 is inconclusive due to crystallographic disorder as well as differences between the two complexes of *Aa*NusB--NusE--BoxA observed in the crystal structure ([Supplementary Figures S1 and S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). NMR data of a complex of *Ec*NusB and *Ec*BoxA also reveal interaction between *Ec*BoxA nucleotide 9 and amino acid residues near *Ec*NusB-118, yet these data do not reveal a single interacting conformation ([Supplementary Figure S3E](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). We believe, therefore, that the relevant BoxA nucleotides do not extend beyond position 8. Figure 2.The BoxA binding site is highly sequence-specific. (**A**) Surface representation in stereo of the *Aa*NusB--NusE--BoxA ternary complex illustrating all protein-BoxA interactions. *Aa*NusB-contributing residues are shown in cyan and *Aa*NusE residues in orange as ball-and-stick models. *Aa*BoxA nucleotide bases are color-coded by base type according to the schematic in panel **B**. (B) Schematic of interactions between *Aa*BoxA and *Aa*NusB--NusE residues as observed in the crystal structure. Amino acid residues in bold are involved in nucleobase specificity. Asterisks denote residues interacting with 2′-OH groups of RNA. Residues labeled in red belong to *Aa*NusE. The base of *Aa*BoxA*-*G9 is shown with dotted lines to indicate that it is disordered. (**C**) Details of *Aa*BoxA-U8 interactions with *Aa*NusB--NusE at the heterodimer interface. (**D**) Surface representation of the chemical shift map of *Ec*NusB upon binding of *Ec*BoxA, presented on the solution structure of *Ec*NusB (PDB ID: 1EY1) with *Ec*BoxA (white) positioned as in the *Aa*NusB--NusE*--*BoxA structure. The residues are colored according to the magnitude of Δδ (*Ec*NusB subtracted from *Ec*NusB--BoxA) ranging from ∼0 ppm (blue) to 1.2 ppm (red) ([Supplementary Figure S3C](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Differences between the chemical-shift-mapped *Ec*BoxA binding site of *Ec*NusB, relative to that observed in the *Aa* crystal structure, are primarily at the N-terminus. Residues A4-R8 (gray) are disordered in the free *Ec*NusB protein and thus no Δδ could be calculated. However, the N-terminal resonances are observed in the *Ec*NusB--BoxA complex, suggesting that this region is stabilized by interactions with *Ec*BoxA*.* Similarly, exchange-broadened residues S119-K121, also for which no Δδ could be calculated, are shown in gray.

The NusB-NusE interface is conserved across *A. aeolicus* and *E. coli*
-----------------------------------------------------------------------

The comparison between the crystal structures of *Aa*NusB--NusE--BoxA (this work) and *Ec*NusB--NusE ([@B4]) shows that the r.m.s.d. for the NusB components, the NusE components and the NusB--NusE complexes are 1.5, 0.8 and 1.7 Å, respectively. The structures show that 6 out of 11 NusB and all 10 NusE residues involved in NusB--NusE heterodimer formation are conserved between the two species, with buried surface areas of 1620 and 1626 Å^2^ for the *Aa* and *Ec* complexes, respectively. The NusB--NusE interface is dominated by hydrophobic interactions and assisted by additional electrostatic interactions between the two proteins. Almost all interactions can be complemented in a cross-species NusB--NusE complex, indicating that the formation of such a complex is possible. Our genetic complementation experiments of *Aa*NusB in *E. coli* show that an *Aa*NusB--*Ec*NusE complex is indeed formed *in vivo* (*vide infra*).

NMR chemical-shift mapping reveals a similar BoxA binding site for *Ec*NusB
---------------------------------------------------------------------------

The BoxA binding site on *Ec*NusB was determined using NMR chemical-shift differences (Δδ) between the free ([@B29]) and *Ec*BoxA-bound states of *Ec*NusB ([Figure 2](#F2){ref-type="fig"}D and [Supplementary Figure S3C](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). The Δδ shift map reveals a contiguous *Ec*BoxA binding surface spanning part of helix α6 (K101-E106), residues E117 and D118 in the loop connecting helices α6 and α7, and most of helix α7 (S119-D128) ([Figures 1](#F1){ref-type="fig"}A and [2](#F2){ref-type="fig"}D). The largest Δδ are observed near F122, which emphasizes the significance of this conserved amino acid for BoxA recognition. Additionally, all amino acid residues in the *Ec*NusB loop containing Y69-G78 show changes in chemical shift upon *Ec*BoxA binding.

The orientation of *Ec*BoxA on the *Ec*NusB surface was determined using Δδ values obtained upon binding of *Ec*BoxA mutants U1C and A9C. *Ec*NusB-D118N was employed in these NMR experiments as this mutant binds *Ec*BoxA with higher affinity in the absence of *Ec*NusE ([@B30]). In the D118N/BoxA-U1C spectrum, small Δδ (∼0.1 ppm) are observed for residues L74, E81, K101, N105, I134 and K139, with the largest Δδ for K101 and K139 ([Supplementary Figure S3D](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). In the D118N/BoxA-A9C spectrum, small Δδ (∼0.1 ppm) are observed for I27, R72, E106, A116, D117 and N118 NH's ([Supplementary Figure S3E](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). These data indicate that the 3′-end of *Ec*BoxA is near the N-terminus of *Ec*NusB helix α6, with nucleotides 8 and 9 near the A116-D118 loop. The *Ec*BoxA binding site on *Ec*NusB, as well as the orientation of *Ec*BoxA on the *Ec*NusB surface, is consistent with the *Aa*NusB--NusE--BoxA crystal structure ([Figure 2](#F2){ref-type="fig"}A and D).

NusB-F122 is important for both cellular and λN-mediated antitermination
------------------------------------------------------------------------

NusB is involved in both cellular and phage λ functions in *E. coli*, being conditionally required for cell growth at low temperatures and λ growth at 42°C ([@B31]). Therefore, *EcΔnusB* cells possess a characteristic cold-sensitive growth phenotype at temperatures below 30°C. Compared to wild-type (wt) *Ec* cells (*nusB^+^*), the *EcΔnusB* cells grow slower at 37°C, but at a comparable rate at 42°C. However, the *EcΔnusB* cells do not support formation of wt λ (λ^+^) plaques during phage infection at 42°C. These two functions of NusB can be efficiently restored through *trans-*expression of wt *Ec*NusB from a plasmid and is the molecular basis for genetic complementation ([@B28]).

The BoxA binding site on NusB is a region of high phylogenetic conservation, particularly along its C-terminal α-helix (α7) ([@B29]). As seen in the *Aa*NusB--NusE--BoxA structure, the semi-exposed and conserved aromatic residue in α7, NusB-F122, exhibits ring stacking with the U8 nucleobase ([Figure 2](#F2){ref-type="fig"}C). In order to test its importance for NusB function, *Ec*NusB-F122 was mutated to aspartic acid and analyzed *in vivo* for its ability to complement *EcΔnusB* cells in the support of *E. coli* and phage λ growth ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)).

The *EcnusB-F122D* mutant is defective as compared to *EcnusB^+^*, which is demonstrated by its cold-sensitivity and inability to promote λ growth ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). The mutant protein is correctly folded, as shown by minimal differences between the NMR spectra ([Supplementary Figure S4A and B](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)) and similar retention times on a size exclusion column as wt *Ec*NusB. The wt *Ec*NusB binds to *Ec*BoxA in a 1:1 complex with a *K*~d~ = 2 µM ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). However, *Ec*NusB-F122D did not detectably bind *Ec*BoxA as measured by either ITC or NMR when present in a 1 : 1 ratio. It remains to be determined how this single point mutation, which would potentially result in a minimal loss of protein--RNA interactions, can abolish binding of BoxA. Nevertheless, it is the only known *EcnusB* missense mutation resulting in defects in both cellular and phage λ antitermination activities. Two previously known missense mutations, *EcnusB5* ([@B32]) and *EcnusB101* ([@B33; @B34; @B35]) show effects mostly in phage λ antitermination activities, and the effect of *EcnusB101* is only observed in conjunction with *EcnusA* or *EcnusE* mutations, being otherwise neutral ([@B33]).

Complementation by *Aa*NusB in *E. coli* is BoxA-sequence dependent
-------------------------------------------------------------------

The functional homology between the *Aa* and *Ec*NusB proteins has been assessed in a genetic complementation assay using *EcΔnusB* cells. Once again, the cellular and λ growth defects of the *EcΔnusB* cells can be compensated by the *trans*-expression of functional *Ec*NusB from a plasmid ([@B28]) ([Figure 3](#F3){ref-type="fig"}A and B). Unlike cells transformed with the control vector, cells transformed with the *Ec*NusB plasmid grow normally at 30 and 37°C. Under the same growth conditions, the expression of *Aa*NusB from plasmid DNA also restores the growth of *EcΔnusB* cells at 30 and 37°C. *Aa*NusB is therefore capable of complementing *Ec*NusB in the context of the protein's cellular functions, most likely through productive interactions with *Ec*BoxA and *Ec*NusE during rRNA synthesis. This interpretation was validated using ITC, which revealed that *Ec*BoxA binds to *Aa*NusB ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Figure 3.Complementation by *Aa*NusB in *E. coli* is BoxA-sequence dependent. (**A**) Growth complementation assay of *EcΔnusB* cells with NusB expressed from plasmid DNA. The *EcΔnusB* cells were transformed with plasmids expressing *Ec*NusB (pAB47), *Aa*NusB (pKM772) or with the control pET vector. The growth of transformants was measured by incubating cells on L medium containing 50 µg/ml ampicillin at 30°C for 2 days, or at 37 or 42°C for 1 day ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). (**B**) Plaque assays demonstrating the complementation of *nusB*-deficient λ growth by *trans*-expression of *Ec* or *Aa*NusB from plasmid DNA. By contrast to phage λ^+^, λ*nin5* does not require NusB for phage growth and was thus used as a positive control for plaque formation. A mutant derivative of λ, λ*boxA9*, has three base changes that create a BoxA RNA that is identical to *Ec*BoxA. It gains the ability to plaque and illustrates that complementation by *Aa*NusB is dependent on specific NusB-BoxA interactions. (**C**) Comparison of BoxA RNA sequences for *Aa*, *Ec*, λ^+^ and λ*boxA9*. Nucleotides in underlined boldface indicate differences in BoxA sequences relative to that of *Aa*BoxA*.* (**D**) Other λ derivatives with *boxA* mutations that affect λN-dependent antitermination activity (indicated in underlined boldface) and their reported *K*~d~ values ([@B30]). Plaquing ability of λ carrying these mutations is shown. The ++ indicates the enhanced ability to make plaques by the A8U mutant ([@B52]).

Contrasting results for genetic complementation are observed in the λ-related activities of *Ec*NusB. Here, λ*nin5* ([@B36]) is used as a control, as it is known to form plaques even in the absence of *Ec*NusB ([@B37]). The λ^+^ infection of *EcΔnusB* cells expressing *Ec*NusB from a plasmid generates plaques, whereas, in cells expressing *Aa*NusB from a plasmid, no plaques are generated at 42°C ([Figure 3](#F3){ref-type="fig"}B). By contrast, *Aa*NusB is capable of supporting growth of a phage λ mutant, λ*boxA9*, whose BoxA is identical to *Ec*BoxA ([Figure 3](#F3){ref-type="fig"}C), thus indicating that the *Aa*NusB complementation is BoxA-sequence dependent.

The crystal structure of *Aa*NusB--NusE--BoxA provides a molecular basis for the differences observed for *Aa*NusB complementation of *Ec* cellular versus λN-mediated functions. The *rrn* BoxA sequences of *E. coli* and *A. aeolicus* differ at positions 1, 6 and 9 ([Figure 3](#F3){ref-type="fig"}C). Structural analysis suggests that two of these differences are likely to be insignificant. A BoxA-C6U substitution would have minimal effects on binding, as the interaction between O2 of the pyrimidine base with *Aa*NusB-S128 would be conserved ([Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). A substitution from N4 to O4 on the pyrimidine ring would result in the loss of a hydrogen bond with phosphate O2 of *Aa*BoxA-C5, and require slight changes in atomic position to avoid electrostatic repulsion between the two oxygen atoms. Similarly, a BoxA-G9A substitution would likely be tolerated, as this nucleotide is a purine in both cases and *Aa*BoxA*-*G9 exhibits no clear base-specific interactions with NusB or NusE proteins. Therefore, the only difference in the *rrn* BoxA sequences of *E. coli* and *A. aeolicus* that would have structural implications for binding is at position 1. As observed in the crystal structure, *Aa*BoxA*-*G1 participates in several hydrogen bonds with *Aa*NusB that would be lost in the case of *Ec*BoxA*-*U1 ([Figure 2](#F2){ref-type="fig"} and [Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Nevertheless, the sum of these changes has very little effect on *Aa*NusB binding and function in *E. coli* ([Figure 3](#F3){ref-type="fig"}A). The greater differences between *Aa* and λBoxA sequences have greater structural implications, by which the latter is incapable of binding to *Aa*NusB ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Once again, a BoxA-C6U substitution would likely have little or no effect (*vide supra*). However, a transversion substitution, BoxA*-*G1C, when accompanied by two other transversion substitutions, BoxA-U8A and G9C ([Figure 3](#F3){ref-type="fig"}C), would lead to the disruption of several hydrogen bonds, resulting in significantly reduced binding energy between λBoxA and the *Aa*NusB--*Ec*NusE complex. *Aa*NusB residues in the BoxA-binding site that are not conserved in *Ec*NusB may cause further disruption of RNA--protein interactions.

Taken together, the major structural difference at position 1 of *Ec*BoxA is tolerated by *Aa*NusB--*Ec*NusE with respect to binding and cellular growth, whereas the added differences at positions 8 and 9 of λBoxA are not tolerated. How *Ec*NusB--NusE tolerates the transversion substitutions at positions 8 and 9 of λBoxA remains to be established. However, previous studies have shown a weaker *Ec*NusB--NusE binding affinity for λBoxA relative to *Ec*BoxA ([@B15],[@B17],[@B30]), most likely caused by forcing a bulkier adenine base into the *Ec*BoxA*-*U8 binding pocket shaped by the *Ec*NusB--NusE interface. This is further supported by the fact that the *Ec*BoxA*-* and λBoxA binding affinities for NusB alone are virtually the same ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Hence, the absence of the binding pocket results in less nucleotide discrimination.

Structural bases for observed mutant phenotypes
-----------------------------------------------

Previous studies have identified mutations in both *Ec*NusB and *Ec*NusE, as well as mutations in λBoxA that affect the efficiency of antitermination. Two of these mutants, *EcnusB5* ([@B32]) and *EcnusE100* ([@B38]), whose single point mutations were identified as *Ec*NusB-Y18D ([@B35]) and *Ec*NusE-R72G, respectively, likely result in the disruption of the *Ec*NusB--NusE heterodimer, as both of these amino acid side chains are buried deep within the protein--protein interface ([@B4],[@B18]). The distant location of these residues in relation to the BoxA binding site suggests that they have little effect on BoxA binding ([Figure 4](#F4){ref-type="fig"}A). Indeed, *Ec*NusB-Y18D maintains *Ec*BoxA-binding affinity relative to wt *Ec*NusB and is otherwise a folded, monomeric protein ([Supplementary Table S2 and Supplementary Figure S4C](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Figure 4.Structural bases for *Ec*NusB and *Ec*NusE mutant phenotypes. (**A**) Stereoscopic view shows the Cα-trace superposition of *Ec*NusB--NusE (PDB ID: 3D3B, in magenta) and *Aa*NusB--NusE--BoxA (this work, in cyan). Also shown are BoxA as a cartoon (colored as in [Figure 2](#F2){ref-type="fig"}) and side chains of amino acid residues whose mutational effects have been previously reported, as ball-and-sticks. (**B** and **C**) Structural bases for the *EcnusB101* and *EcnusE71* mutants through side-chain modeling*.* The *Aa*NusB--NusE--BoxA (this work), *Ec*NusB--NusE (PDB ID: 3D3B), and *Ec*NusB101--NusE (PDB ID: 3IMQ) structures are superimposed. For *Aa*NusB--NusE--BoxA, polypeptide backbones are shown as cartoons (helices as spirals, strands as arrows and loops as tubes) in blue, and nucleotides and amino acid side chains as ball-and-sticks in atomic colors (N in blue, O in red, P in orange, C of RNA in yellow and C of protein in cyan). For *Ec*NusB--NusE and *Ec*NusB101--NusE, polypeptide backbones are not shown for clarity and amino acid side chains are shown as ball-and-sticks but C in magenta. Modeled amino acid side chains are shown as ball-and-sticks but C in white. Potential interactions are shown as dashed lines in black.

The structural bases for *Ec*NusB-D118N and *Ec*NusE-A86D phenotypes ([@B35]), caused respectively by the *EcnusB101* ([@B33; @B34; @B35]) and *EcnusE71* ([@B3]) mutations, are much less obvious. *Ec*NusB-D118N and *Ec*NusB-D118K ([@B30]) are compensatory mutants that rescue λ growth defects induced by a mutation in *Ec*NusA (*EcnusA1*), most likely by enhancing λBoxA affinity for *Ec*NusB-NusE via interaction with asparagine or lysine side chains, which is not possible in the case of the native aspartic acid. Indeed, the crystal structure of *Aa*NusB--NusE--BoxA, which naturally contains a lysine at *Aa*NusB position 118, exhibits contacts between *Aa*NusB-K118 and *Aa*BoxA-G9. Likewise, modeling of *Aa*NusB-K118N reveals favorable interaction potential between the asparagine side chain and the phosphate group of *Aa*BoxA*-*G9 ([Figure 4](#F4){ref-type="fig"}A and B).

By contrast, the addition of these few interactions provided by lysine or asparagine at this position, do not significantly improve binding to *Ec*BoxA. Previous *in vitro* studies using fluorescence anisotropy titrations showed that the *Ec*NusB-D118N and D118K mutants have enhanced *Ec*NusB--NusE binding affinity for λBoxA but not for *Ec*BoxA ([@B30]). Further supporting evidence is provided by experiments with λ*imm21* ([@B35]), whose BoxA RNA is identical to *Ec*BoxA, demonstrating that *Ec*NusB-D118N rescues the growth of phage λ, but not λ*imm21*, in *E. coli* cells carrying the *nusA1* mutation. We propose, therefore, that the selective binding enhancement of the *Ec*NusB-D118K and D118N mutants for λBoxA results from the transversion substitutions at positions 8 and 9 ([Figure 3](#F3){ref-type="fig"}C), in which the additional interactions with BoxA generated by these rescue mutations are of greater impact in the case of λBoxA and are required to rescue phage growth. However, further structural investigation of RNA--protein interactions is necessary, particularly for λBoxA, in order to support this claim.

The *Ec*NusE-A86D mutation, which is far from both the heterodimer interface and the BoxA binding site ([Figure 4](#F4){ref-type="fig"}A), most likely plays another role. An aspartate in this position can be modeled within hydrogen-bonding distance of a conserved arginine (NusE--R31) that is solvent exposed ([Figure 4](#F4){ref-type="fig"}C). In the structure of *Aa*NusB--NusE--BoxA, NusE--R31 forms crystal contacts with the second copy of *Aa*NusB. This may indicate that *Ec*NusE-R31 is involved in the binding of another protein in the antitermination complex, possibly RNAP ([@B39]), and that its interaction with *Ec*NusE-A86D may weaken or preclude its native function. The introduction of a negative charge at this position may also directly disrupt interactions electrostatically. However, *Ec*NusE-A86D, which inhibits growth of λ^+^, does not inhibit growth of λ*imm21* or *Ec* host cells ([@B35]). This suggests that any negative impact posed by *Ec*NusE-A86D is compensated by the greater BoxA affinities in the λ*imm21* and *E. coli* cellular antitermination systems. Whereas, in the case of λ^+^, *Ec*NusE-A86D necessitates a compensatory mutation (*EcnusB101*, *Ec*NusB-D118N) in order to achieve the required λBoxA affinity.

Several phenotypes resulting from mutations in λBoxA have also been observed ([Figure 3](#F3){ref-type="fig"}D). The mutation, λBoxA*-*A8U ([@B39]), actually enhances λN-mediated antitermination. Indeed, BoxA*-*U8, present in both *Aa* and *Ec*BoxA sequences, binds tightly in the pocket formed by the NusB--NusE interface in the crystal structure of *Aa*NusB--NusE--BoxA, and exhibits key base-specific interactions that are likely to be absent in the case of adenine ([Figure 2](#F2){ref-type="fig"}C). Other mutations in λBoxA, including G2U, C5A and U6G, inhibit λN-mediated antitermination and have greatly reduced affinity for the *Ec*NusB--NusE heterodimer ([@B30]), suggesting that transversion substitutions are not tolerated at λBoxA positions 2, 5 or 6 ([Figure 3](#F3){ref-type="fig"}D). It is also evident from the crystal structure of *Aa*NusB--NusE--BoxA that these conserved nucleotides, G2, C5 and C6 (*Aa*BoxA) or G2, C5 and U6 (*Ec* and λBoxA), play significant roles in both cellular and λN-mediated antitermination activities, due to their extensive and specific interactions with NusB residues ([Figure 2](#F2){ref-type="fig"} and [Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)).

The *Aa*NusB-NusE heterodimer forms a contiguous binding site for dsRNA
-----------------------------------------------------------------------

As aforementioned, the 12-mer RNA used in crystallization experiments forms a stable duplex at temperatures below 32°C. Room-temperature crystallization of the *A. aeolicus* ternary complex ([Supplementary Figure S5](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)) led to the discovery of a novel binding site for dsRNA, which is generated by the surface of the NusB--NusE heterodimer ([Figure 5](#F5){ref-type="fig"}A), and is positioned directly adjacent to the BoxA binding site (details in Discussion). Although not as numerous as the interactions with BoxA, the strength of dsRNA binding by NusB--NusE is achieved through several electrostatic interactions between dsRNA backbone atoms and positively-charged protein side chains. The structure reveals six residues of *Aa*NusB (K5, K36, N37, K39, N40 and K113) and four residues of *Aa*NusE (K9, R11, R45 and K46) that contribute to the binding of dsRNA. As virtually all protein-dsRNA contacts are limited to the RNA backbone, the mode of binding is primarily sequence-independent ([Figure 5](#F5){ref-type="fig"}A), with the exception of *Aa*NusE-R45, which has additional interactions with a base pair. The four *Aa*NusE residues are conserved in *E. coli* ([Figure 1](#F1){ref-type="fig"}) and at least three out of the four (R11, R45 and K46) contribute to NusE/S10-dsRNA interaction within the 30 S ribosome subunit (PDB codes 2AVY and 3KIQ). Some of the dsRNA-binding residues of NusB, on the other hand, demonstrate weaker conservation, particularly D39, D42 and S113 (*Ec*NusB). This may indicate a smaller, yet still relevant, contribution of *Ec*NusB in the binding of dsRNA by *Ec*NusB--NusE. Our NMR experiments indicate that *Ec*NusB--dsRNA interaction is more dependent on the high-affinity interaction with *Ec*BoxA ([Supplementary Figure S6](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). Figure 5.Binding of dsRNA by the NusB--NusE heterodimer. *Aa*NusB molecules are colored in blue, *Aa*NusE molecules in wheat and dsRNA in magenta. Orientations in all panels are identical to that in [Figure 2](#F2){ref-type="fig"}A. (**A**) Crystal structure of the *Aa*NusB--NusE--dsRNA ternary complex in stereo. Residues involved in dsRNA binding are depicted as ball-and-sticks with white surface. (**B** and **C**) Superposition of the crystal structures of *Aa*NusB--NusE--BoxA and *Aa*NusB--NusE--dsRNA, illustrating the contiguous binding regions for *Aa*BoxA and dsRNA. In panel C, the protein surface representation is colored by vacuum-electrostatic potential (red, negative; blue, positive), which depicts the *Aa*BoxA and dsRNA binding sites as a contiguous positively-charged surface.

DISCUSSION
==========

The phenomena of transcription termination and antitermination are best characterized in the λN-mediated system ([@B40; @B41; @B42]). Hence, the discussion will be focused on the λN-mediated transcription antitermination (For a discussion on other systems, see [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)). The λN protein, whose interaction with RNAP is facilitated by host proteins (NusA, NusB, NusE and NusG), binds to the λ*nut* site in the nascent RNA ([@B43]). How λN assists RNAP to read through terminators remains unclear ([@B44]), but its site of action appears to be in proximity to the RNA:DNA hybrid of the transcription elongation complex ([@B45]). As mentioned previously, the assembly of the complete antitermination complex is required for processive antitermination and begins with the formation of the NusB--NusE--BoxA complex.

We have determined the crystal structure of the NusB--NusE--BoxA ternary complex from *A. aeolicus*, indentifying key protein--RNA interactions at atomic resolution. The equivalence of the *Ec*BoxA and *Aa*BoxA binding sites enables detailed interpretation of these findings with respect to the biologic functions of the NusB and NusE proteins. The structure shows that the BoxA sequence comprises 8 nt. The extensive interaction between NusB and BoxA illustrates not only the strength of binding energy ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr418/DC1)), but also the significance of nucleotide-sequence specificity. The direct contribution of NusE to the binding of BoxA is limited, suggesting that the importance of NusE in the initiation of transcription antitermination is demonstrated by additional interactions with other antitermination complex components.

The NusB--NusE complex binds an additional RNA component not previously observed. We have shown that a binding site for dsRNA is generated by the formation of the NusB--NusE heterodimer, which is contiguous with the 5′-end of the BoxA binding site ([Figure 5](#F5){ref-type="fig"}B and C). The binding of dsRNA involves primarily RNA-backbone interactions, indicating that this dsRNA binding site is independent of sequence, provided that canonical A-form RNA secondary structure is maintained. Nonetheless, some sequence specificity may be imposed by the conserved NusE-R45 to discriminate generic dsRNA species from the physiological ligand of the NusB--NusE heterodimer.

The only defined dsRNA component involved in λN-mediated antitermination, particularly within proximity to BoxA, is the stem-loop structure formed by BoxB ([Figure 6](#F6){ref-type="fig"}A). We propose, therefore, that the dsRNA observed in these crystal structures may provide an accurate representation of the BoxB stem-loop and that NusB and NusE cooperatively form contiguous binding surfaces for both BoxA and BoxB components ([Figures 5](#F5){ref-type="fig"}C and [6](#F6){ref-type="fig"}B). As previously discussed, the conserved NusE residues demonstrate similar dsRNA interactions within the ribosome. Thus, the dual functionality of NusE may involve, not only protein--protein interactions, but also conserved protein-dsRNA interactions: with rRNA in translation, with BoxB in antitermination. Figure 6.Models for the λN-mediated antitermination subcomplex and complete complex. (**A**) Representation of the λ*nutR* RNA showing the possible spatial relationship between BoxA (yellow) and BoxB (magenta) components. (**B**) Superimposed components of the antitermination complex with known structures, including *Aa*NusB--NusE--BoxA and *Aa*NusB--NusE--dsRNA (this work), the N-terminal α-helix of λN protein bound to BoxB (PDB ID: 1QFQ, black), the C-terminal domain of *Ec*NusG in its complex with *Ec*NusE (PDB ID: 2KVQ, green), and the N-terminal domain of *Ec*NusG (PDB ID: 2K06, green). The N- and C-terminal domains of *Ec*NusG were positioned relative to one another by superimposing them with the N- and C-terminal domains, respectively, of *Aa*NusG (PDB ID: 1NPP). (**C**) Left: the NusB--NusE--BoxA--spacer--BoxB--λN subcomplex; Right: updated model for the complete λN-mediated antitermination complex, illustrating all known interactions. Nus factors B (blue) and E (wheat) cooperatively bind BoxA and BoxB (this work). λN protein (gray) binds BoxB ([@B8; @B9; @B10; @B11]) and also possibly NusE (this work). λN protein binds RNAP near the transcription bubble ([@B45]). NusA (red) stabilizes these interactions by interacting with the λ*nut* spacer RNA between BoxA and BoxB ([@B12]), and with λN protein ([@B51]) through NusA SKK (S1-KH1-KH2) and AR1 domains, respectively, while anchoring the complex to RNAP through the NusA NTD and AR2 domains ([@B48; @B49; @B50]). NusG (green) further stabilizes the complex through its CTD interaction with NusE ([@B5]), also serving as an anchor to RNAP through its NTD ([@B53]).

It is known that the BoxB stem loop binds to phage λN protein ([@B8; @B9; @B10; @B11]). To address the implications of this model in the λ system, the complexes presented in this work were structurally aligned with an NMR structure of the BoxB stem-loop bound to the N-terminal α-helix of λN protein (PDB ID: 1QFQ) ([@B11]). The BoxB structure aligns with the dsRNA observed in this work with near precision, and positions the λN α-helix within close proximity to *Aa*NusE without steric clash ([Figure 6](#F6){ref-type="fig"}B). Previous studies have shown that the presence of NusB and NusE increases the efficiency of a λN-like protein (Nun) to modify transcription elongation ([@B46]), which, by this model, would result from the formation of a stable NusB--NusE--BoxA--BoxB complex that enables more effective recruitment of λN/Nun protein.

It is indicated that NusG promotes anchoring of a subcomplex, which we suggest to include NusB, NusE, BoxA, BoxB and λN protein ([Figure 6](#F6){ref-type="fig"}C, left), to RNAP through its interactions with NusE ([@B5]). Superposition of previous structures of NusG ([@B47]) and the NusE--NusG complex ([@B5]), with the combined crystal structures presented in this work, is shown in [Figure 6](#F6){ref-type="fig"}B. Association of NusA with RNAP ([@B48; @B49; @B50]) aids in the recruitment of the subcomplex through NusA interactions with λN protein ([@B51]) and the λ*nut* spacer RNA ([@B12]), which is located between BoxA and BoxB. Together, the network of interactions implies a highly compact quaternary structure for the complete antitermination complex ([Figure 6](#F6){ref-type="fig"}C, right). These findings demonstrate the complexity of structural interplay among various components of the antitermination machinery, and provide a framework for studying the underlying molecular mechanisms.
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